Hydrophilic acrylic intraocular lens as a drug-delivery system for fourth-generation fluoroquinolones.
OBJECTIVE
To evaluate the ability and safety of a hydrophilic acrylic intraocular lens (IOL) as a drug-delivery system for commercially available gatifloxacin and moxifloxacin.


METHODS
David J. Apple, MD, Laboratories for Ophthalmic Research, John A. Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, Utah, USA.


METHODS
Thirty rabbits were divided into 2 similar groups. In Group A (15 rabbits, 30 eyes), hydrophilic acrylic IOLs (C-flex, Rayner Intraocular Lenses, Ltd.) presoaked for 24 hours in commercially available solutions of gatifloxacin 3 mg/mL or moxifloxacin 5 mg/mL were implanted after evacuation of the crystalline lens. Group B (15 rabbits, 30 eyes) had topical preoperative and postoperative cataract prophylaxis with gatifloxacin 3 mg/mL or moxifloxacin 5 mg/mL; IOLs that were not presoaked were also implanted after evacuation of the crystalline lenses. In both groups, aqueous humor samples were taken 4, 8, or 12 hours after IOL implantation (5 eyes at each time point) to determine the antibiotic concentrations. Clinical examinations were performed 24 hours postoperatively.


RESULTS
The antibiotic concentrations in Group A (presoaked IOLs) were statistically significantly higher than those in Group B (topical) for both antibiotics in all postoperative samples except moxifloxacin at 12 hours. In both groups, there was no statistically significant difference between the concentrations of the 2 antibiotics. No eye showed signs of clinical toxicity.


CONCLUSIONS
Results show the C-flex IOL is a safe and effective drug-delivery system for fourth-generation fluoroquinolones.
Kleinmann
Guy
G
David J Apple, MD, Laboratories for Ophthalmic Research, John A Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, UT, USA. guy.kleinmann@hsc.utah.edu
Apple
David J
DJ
Chew
Jesse
J
Hunter
Brian
B
Stevens
Scott
S
Larson
Scott
S
Mamalis
Nick
N
Olson
Randall J
RJ
D000180:Acrylic Resins; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001082:Aqueous Humor / Q000378:metabolism; D001372:Aza Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D016503:Drug Delivery Systems; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077734:Gatifloxacin; D019654:Lens Implantation, Intraocular; D007908:Lens, Crystalline / Q000601:surgery; D007910:Lenses, Intraocular; D000077266:Moxifloxacin; D011804:Quinolines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011817:Rabbits
D000180:Acrylic Resins; D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077734:Gatifloxacin; D000077266:Moxifloxacin